Peony RedPub Date : 2000-12-01DOI: 10.2307/j.ctvbtzm0f.4
김범렬, 강만수, 권우형, 윤성수, 김홍진
{"title":"2","authors":"김범렬, 강만수, 권우형, 윤성수, 김홍진","doi":"10.2307/j.ctvbtzm0f.4","DOIUrl":"https://doi.org/10.2307/j.ctvbtzm0f.4","url":null,"abstract":": Modulation of α 1 β 2 γ 2GABA-A receptor subpopulation expressed in the basal ganglia region is a conceptually novel mode of pharmacological strategy that offers prospects to tackle a variety of neurological dysfunction. Although clinical findings provided compelling evidence for the validity of this strategy, the current chemical space of molecules able to modulate the α 1/ γ 2 interface of the GABA-A receptor is limited to imidazo[1,2-a ]pyridine derivatives that undergo rapid biotransformation. In response to a deficiency in the chemical repertoire of GABA-A receptors, we identified a series of 2-(4-fluorophenyl)-1 H -benzo-[ d ]imidazoles as positive allosteric modulators (PAMs) with improved metabolic stability and reduced potential for hepatotoxicity, where lead molecules 9 and 23 displayed interesting features in a preliminary investigation. We further disclose that the identified scaffold shows a preference for interaction with the α 1/ γ 2 interface of the GABA-A receptor, delivering several PAMs of the GABA-A receptor. The present work provides useful chemical templates to further explore the therapeutic potential of GABA-A receptor ligands and enriches the chemical space of molecules suitable for the interaction with the α 1/ γ 2 interface.","PeriodicalId":163524,"journal":{"name":"Peony Red","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121557852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peony RedPub Date : 1982-11-01DOI: 10.2307/j.ctvbtzm0f.32
송종운, 박주섭
{"title":"30","authors":"송종운, 박주섭","doi":"10.2307/j.ctvbtzm0f.32","DOIUrl":"https://doi.org/10.2307/j.ctvbtzm0f.32","url":null,"abstract":"In a retrospective cohort study involving 258 patients presented between 2016 and 2018, 30 patients (18 women and 12 men), aged 45–84 years were described, who developed pneumonitis or exhibited lack of efficacy during the treatment with nivolumab, ipilimumab, azacitidine or idarubicin for acute myeloid leukaemia (AML) [ dosages, routes and durations of treatments to reactions onsets not stated; not all outcomes stated ]. This report describes a 71-year-old woman (case 1) from supplemental table 1: woman, who had AML, started receiving treatment with two cycles nivolumab ipilimumab along with azacitidine. However, no response was noted. She also developed nivolumab, ipilimumab and azacitidine induced grade 5 pneumonitis. Nivolumab and ipilimumab were discontinued. Eventually, she died due to pneumonitis. This report describes a 72-year-old woman (case 2) from supplemental table 1: The woman, who had AML, started receiving treatment with two cycles of nivolumab and ipilimumab along with azacitidine. However, no response was noted. She also developed nivolumab, ipilimumab and azacitidine induced grade 5 pneumonitis. Nivolumab and ipilimumab were discontinued. Eventually, she died of pneumonitis. This report describes a 63-year-old woman receiving treatment with four nivolumab However, she developed nivolumab idarubicin pneumonitis. This report describes a 69-year-old man (case cancer and AML, started receiving treatment with three cycles of nivolumab along with azacitidine. However, he developed nivolumab and azacitidine induced grade 5 pneumonitis. He discontinued nivolumab. Eventually, azacitidine pneumonitis resolved. nivolumab. of AML. This report describes a 83-year-old man (case from who had started receiving treatment with eleven cycles of nivolumab along with azacitidine. However, he developed nivolumab and induced pneumonitis. Therefore, nivolumab was discontinued. However, he died","PeriodicalId":163524,"journal":{"name":"Peony Red","volume":"112 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1982-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124133795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
求助内容：
应助结果提醒方式：